CURRENT CONCEPTS IN RADIOTHERAPY FOR BENIGN DISORDERS

CurrentConceptsinRadiotherapyforBenignDisorders1-0-25kapak

Furunculosis, Hidradenitis Supurativa, Paronychia

Hüseyin TEPETAMa , Şule KARABULUT GÜLb
aİstanbul Dr. Lütfi Kırdar Kartal City Hospital, Clinic of Radiation Oncology, İstanbul, Türkiye
bUniversity of Health Sciences Faculty of Medicine, Kartal Dr. Lütfi Kırdar City Hospital, Department of Radiation Oncology, İstanbul, Türkiye

Tepetam H, Karabulut Gül Ş. Furunculosis, hidradenitis supurativa, paronychia. In: Uysal B, Gamsız H, eds. Current Concepts in Radiotherapy for Benign Disorders. 1st ed. Ankara: Türkiye Klinikleri; 2025. p.66-71.

ABSTRACT
Radiotherapy (RT) has been used for a long time in the treatment of various benign infectious and non-infectious diseases. After the discovery of X-rays and radioactivity, the anti-inflammatory effects of low-dose radiation were recognized early and started to be applied. However, due to the discovery of antibiotics and anti-inflammatory drugs and the carcinogenic risks of radiation, this use was largely abandoned in the second half of the 20th century. Today, new searches are emerging in the treatment of infectious diseases due to increasing antibiotic resistance. In this context, it seems possible that radiotherapy will come to the agenda again as an option. Technological advances, the ability to finetune radiation doses and a better understanding of radiobiology have contributed to the expansion of the areas of use of radiotherapy. In particular, the ”osteoimmunomodulatory” effects of low-dose (<1 Gy) radiotherapy are remarkable in musculoskeletal and rheumatic diseases. In this review, we wanted to emphasize that radiotherapy can also be an alternative treatment in selected patients with inflammatory diseases.

Keywords: Hidradenitis suppurativa; paronychia; radiotherapy; inflammation

Referanslar

  1. Desjardins AU. Radiotherapy for inflammatory conditions. JAMA. 1941;116:225-31. [Crossref]
  2. Seegenschmiedt MH, Micke O, Muecke R. Radiotherapy for non-malignant disorders: State of the art and disorders update of the evidence-based practice guidelines. Br J Radiol. 2015;88:1-11. [Crossref]  [PubMed]  [PMC]
  3. Levy SB, Bonnie M. Antibacterial resistance worldwide : causes , challenges oath responses. Nat Med. 2004;10(12S):S122-9. [Crossref]  [PubMed]
  4. Smyth CJ, Freyberg RH, Peck WS. roentgen therapy for rheumatic disease. JAMA. 1941;116:1995-2001. [Crossref]
  5. Weissmann T, Rückert M, Putz F, et al. low dose radiotherapy of osteoarthritis: from biological findings to clinical effects-challenges for future studies . Strahlenther Oncol. 2023;199:1164-72. [Crossref]  [PubMed]  [PMC]
  6. Desjardins AU. Radiotherapy for inflammatory conditions. J Am Med Assoc. 1931;96:401-8. [Crossref]
  7. Desjardins AU. Dosage oath method of roentgen therapy for inflammatory conditions. Radiology. 1939;32:699-707. [Crossref]
  8. McLaughlin CW. the surgical treatment of large carbuncles in diabetic oath non-diabetic individuals. Surgery. 1942;11:797-809.
  9. Coyle RR. odd oath ends of x-ray work , including some cases of carbuncle med. Electrol Radiol. 1906;7(1):39-142.
  10. Dunham K. Treatment of carbuncles by the Roentgen Ray. Am J Roentgenol. 1916;3:259-60.
  11. May EA. Roentgen therapy in acute inflammatory conditions. Radiology. 1929;14:411-5. [Crossref]
  12. Belisario JC, Pugh RE. Threshold erythema dose of roentgen rays. I. Review of the literature oath comment on variation of doses in use in Australia, The United States Noath England. Arch Dermatol Syphilol. 1942;45(3):519-43. [Crossref]
  13. Pohle EA. Studies of the roentgen erythema of the human skin I. Skin capillary changes after exposure to unfiltered radiation. Radiology 1926;6:236-45. [Crossref]
  14. Belisario JC. A discussion on the skin erythema dose with Röntgen rays : some biological implications Br J Radiol. 1952;25(294):326-35. [Crossref]  [PubMed]
  15. Bergler-Czop B, Hadasik K, Brzezińska-Wcisło L. Acne inversa: difficulties in diagnostics oath therapy. Postepy Dermatol Allergol. 2015;32:296-301. [Crossref]  [PubMed]  [PMC]
  16. Velpeau A. Aissele. In: BechetJeune Z, ed. Medical Dictionary, General Repertoire of Medical Sciences Compatible with Theoretical and Practical. Volume 2. Paris: 1839. p.1839-91.
  17. Verneuil A. Etudes sur les tumors de la peau; de quelques maladies des glandes sudoripares. Arch Gen Med. 1854;4:447-68.
  18. Plewig G, Kligman AM. Acne: Morphogenesis and Treatment. Berlin: Springer-Verlag; 1975. p.192-3. [Crossref]
  19. Jemec GBE. Clinical practice hidradenitissuppurativa . N Engl J Med [Internet]. 2012;366:158-64. [Crossref]  [PubMed]
  20. Lipsker D, Severac F, Freysz M, Sauleau E, Boer J, Emtestam L, et al. The ABCs of Hidradenitis Suppurativa: A Validated Glossary on how to Name Lesions. Dermatology. 2016;232:137-42. [Crossref]  [PubMed]
  21. Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitissuppurativa oath its potential precursor lesions. J Am Acad Dermatol. 1996;35:191-4. [Crossref]  [PubMed]
  22. Garg A, Kirby JS, Lavian J, et al. Sex-and age-adjusted population analysis of prevalence estimates for hidradenitissuppurativa in the United States. JAMA Dermatol. 2017;153:760-4. [Crossref]  [PubMed]  [PMC]
  23. Revuz JE, Canoui-Poitrine F, Wolkenstein P, Viallette C, Gabison G, Pouget F, et al. prevalence oath factors associated with hidradenitissuppurativa: results from two case-control studies. J Am Acad Dermatol. 2008;5:596-601. [Crossref]  [PubMed]
  24. Horváth B, Janse IC, Blok JL, et al. Hurley staging refined: a proposal by the Dutch hidradenitissuppurativa expert Group. Actaderm Venereol.2016;97:412-3. [Crossref]  [PubMed]
  25. Melnik BC, Plewig G. Impaired notch signalling: the unifying mechanism explaining the pathogenesis of hidradenitissuppurativa (acne inversa). Br J Dermatol [Internet]. 2013;168:876-8. [Crossref]  [PubMed]
  26. Kimball AB, Okun MM, Williams DA, Gottlieb AB, Papp KA, Zouboulis CC, et al. two Phase 3 Trials of Adalimumab for hidradenitis Suppurativa. N Engl J Med. 2016;375:422-34. [Crossref]  [PubMed]
  27. Madan V, Hindle E, Hussain W, August PJ. Outcomes of treatment of nine cases of recalcitrant severe hidradenitissuppurativa with carbon dioxide laser. Br J Dermatol. 2008;159:1309-14. [Crossref]  [PubMed]
  28. Tierney E, Mahmoud BH, Hexsel C, Ozog D, Hamzavi I. Randomized control trials for the treatment of hidradenitissuppurativa with a neodymium-doped yttrium aluminum garnet laser. Derm Surg. 2009;35(8):1188-98. [Crossref]  [PubMed]
  29. Zouboulis CC, Desai N, Emtestam L, Hunger RE, Ioannides D, Juhász I, et al. European S1 guideline for the treatment of hidradenitissuppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29:619-44. [Crossref]  [PubMed]
  30. Posch C, Monshi B, Quint T, Vujic I, Lilgenau N, Rappersberger K. The role of wide local excision for the treatment of severe hidradenitissuppurativa (Hurley grade III): Retrospective analysis of 74 patients. J Am Acad Dermatol.2017;77:123-9.e5. [Crossref]  [PubMed]
  31. Alikhan A, Sayed C, Alavi A, Alhusayen R, Brassard A, Burkhart C, et al. north american clinical management guidelines for hidradenitissuppurativa : A publication from the United States oath Canadian hidradenitissuppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary oath procedural management. J Am Acad Dermatol. 2019;81(1):76-90. [Crossref]  [PubMed]  [PMC]
  32. Schenck SG. Hidradenitis suppurativa axillaris; an analysis of 54 cases treated with roentgen rays. Radiology. 1950;54(1):74-7. [Crossref]  [PubMed]
  33. Steiner K, Grayson LD. hidradenitissuppurativa of the adult oath its management. BUT Arch Derm. 1955;71(2):205-11. [Crossref]  [PubMed]
  34. Zeligman I. Temporary X-ray epilation therapy of chronic axillary hidradenitissuppurativa. Arch Dermatol. 1965;92(6):690-4. [Crossref]  [PubMed]
  35. Johnson SA Jr, Forbes RC. Hidradenitis in a patient with AIDS: palliation with superficial radiation. South Med J. 1994;87(4):549. [Crossref]  [PubMed]
  36. Frohlich D, Baaske D, Glatzel M. Radiotherapy of hidradenitissuppurativa : still valid today? Strahlenther Oncol. 2000;176:286-9.
  37. Trombetta M, Werts ED, Parda D. The role of radiotherapy in the treatment of hidradenitis suppurativa: case report oath review of the literature. Dermatol Online J. 2010;16(2). [Crossref]  [PubMed]
  38. Patel SH. Radiation Therapy for Chronic hidradenitis Suppurativa. J Nucl Med Radiate Ther. 2013; 4:146. [Crossref]
  39. Sakyanun P, Vongvanichvathana T, Lertsanguansinchai P. Radiation therapy in chronic hidradenitissuppurativa: case report. Radiate Oncol J.2022;40(1):79-85. [Crossref]  [PubMed]  [PMC]
  40. Shafritz AB, Coppage JM. Acute oath chronicle paronychia of the hand. J Am Acad Orthop Surg. 2014;22:165-74. [Crossref]  [PubMed]
  41. Rigopoulos D, Larios G, Gregoriou S, Alevizos A. Acute oathchronicle paronychia. Am Fam Physician. 2008;77:339-46.
  42. Rockwell PG. Acute oath chronicle paronychia. Am Fam Physician. 2001;63:1113-6.
  43. Heidary N, Naik H, Burgin S. Chemotherapeutic agents oath the skin: an update. J Am Acad Dermatol. 2008;58:545-70. [Crossref]  [PubMed]
  44. Hu JC, Sadeghi P, Pinter-Brown LC, et al. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol. 2007;56:317 . [Crossref]  [PubMed]
  45. Reyes-Habito CM, Roh EK. Cutaneous reactions to chemotherapeutic drugs oath targeted therapy for cancer: Part II. targeted therapy. J Am Acad Dermatol. 2014;71(2):217. [Crossref]  [PubMed]